A very welcome 4% SP increase today. Perhaps more going on than just the above good news
Printable View
A very welcome 4% SP increase today. Perhaps more going on than just the above good news
? Singapore. That of course has been a frequent refrain.
Release Just out
PACIFIC EDGE ANNOUNCES AGREEMENT WITH NORTHERN HEALTH IN AUSTRALIA
https://www.nzx.com/announcements/384374
And about time too.
Very encouraging progress that they are going for Monitor initially followed by Triage for Haematuria.
Was wondering when the thicker side of the Tasman Plate might finally get on with some sort of acceptance.:)
This is great news - and hopefully it's the start of a positive trend for uptake in Oz.
The announcement adds further credibility to the PEB offering and, as the SP is news-driven, upward momentum is a pretty sure thing as more Aussie health services inevitably come onboard.
Of course, this announcement is relatively minor in the overall scheme of things and progress remains painfully slower than most holders would have hoped or wanted - but it's definitely going in the right direction.
Let's hope the US and Singapore prospects are receiving the announcements too and are increasingly motivated to jump on the PEB train.
I'm looking forward to the next 12 months or so with anticipation, especially with the new CEO at the helm.
As those who know the medical profession have stated, changing practice is a long, drawn out process of small wins like that announced today at Northern Health Australia. We are some ways off yet, but I do feel that CXBladder is inexorably gaining acceptance and a tipping point will be reached at some point where it will become the industry norm. All bets are off as to what that will translate to in share price but it could be a life changer for those who got in, even modestly, only a year or two ago.
What is also important is that the state of Victoria operates its public hospitals in a group, of which Northern Health is just one. Also part of the group is the well regarded Peter MacCullum Cancer Center. So a successful trial at NH is likely to result in a much wider state-wide roll out and some stronger reference sites.
http://nzx-prod-s7fsd7f98s.s3-websit...380/361302.pdf
Bryan must think the shares are good buying at $1.25.
Yes, so did we. Quite a surge of demand pushing SP through to close today. Positive sign for directional movement. Soon to push through back into 1.4 plus range as expected (see previous posts).
More positive news in the works prompting the volume up on close likely behind the scenes.
https://www.odt.co.nz/business/leavi...c-edge-success
It must have been pretty trying at times but what a great job he's done.
Wait for it, next buying push will see SP back in high 1.4's next level soon enough.
Up 5c today on good volume. Wonder what that is all about?
That was a surprise I wasn't expecting... 5.8 million shares sold end of week dropping the SP by almost 6%! Any thoughts on what happened there?
Yep, good news needs to keep coming, like a more positive response from the AUA about Cxb efficacy or contracts from more medical institutions, or a significant increase in lab throughput etc otherwise the current valuation is pretty toppy based on current fundamentals, hence expect a lot of volatility as perceptions about take up of Cxb change.
The cap rate on PEB atm suggests that the market expects a significant uptake over the next year or so and are happy to sit it out...well most anyway. On the other hand someone may have needed to buy big on Xmas presents!
Funds rebalancing, 850 man
Nah. Rebalance is just another word for a reality check. You are not going to rebalance downwards if there is a frequent string of positive announcements about adoption. In fact institutions will rebalance upwards should that be the case. Its just changing perceptions over the length of time it is going to take to attain significantly more adoption and with it significantly more lab throughput. In the absence of news there will always be a rethink of strategy driven by uncertainty.
Having said that it’s just a matter of time before increasing adoption takes place. If a medical facility like Johns Hopkins widely adopts Cxb as a clinical basis for determining whether a cystoscopy is necessary then the SP will react very positively. I would not want to be short if that announcement was made, nor if any other significant adoption announcement was made.
No news....uncertainty....cover the downside.... slow slide backwards
Indeed DK but they need more than a successful study result they need adoption on a bigger scale to support the current valuation
This came out this morning adding further " grist for the mill".
https://www.docwirenews.com/gu-oncol...ce-cystoscopy/
As a refresher, did PEB ever get that lump sum payment/reimbursement for the initial testing that was done as part of the ramp up to full approval by medicare, medicaid, and blue cross/blue shield. I think it was mentioned that there could be a reimbursement payment of something like 30 Million on lab testing of a normal invoiced value of 90+ Million. It was an optimistic view, that I've yet to find any follow up on? Would have been a nice little non dilutive cash bump.. Probably missed an announcement around this in the last 18 months of share price excitement!
No, payment not received nor was it ever very likely imo.
Cxbladder is still not covered by Bluecross or any of the US Insurers. With sleight of hand there was the announcement that United Healthcare now covered the tests but this was under its medicare policy only, not those it underwrites itself.
SP down 15% in 2 weeks, time for some good news methinks
With new funds raised @ $1.35 and the employment of more "marketing" executives to promote the advantages of Cxb, whats happened? In general no news is good news but i'm not sure this applies here.
There is definitely a reassessment of risk on asset inherent here, reflected in the slow decline of the SP
Thanks Barney. Dr Meintjes certainly has the right CV and his US commercial experience will be invaluable. I remain convinced of the high value CxBladder.
Not heard much from PEB, wondering what they are doing will all those millions, hopefully great things.
Anyone know the Q1 announcement date? Thanks
DHBs sales are never going to save this company. They have been great in trialing the tech. The only way it can succeed is to sell big overseas.
Not sure if this one has been shared before in the forum. It is a recent research paper on CXBladder Resolve.
The Diagnostic Performance of Cxbladder Resolve, Alone and in
Combination with Other Cxbladder Tests, in the Identification
and Priority Evaluation of Patients at Risk for Urothelial
Carcinoma
https://www.google.com/url?sa=t&sour...D7hCPTbP_PYtEJ
No news from PEB is not good news for the share price - at risk of dropping below $1 mark!
He's pretty active on Linkedin advertising for more staff!
PEB really need to get a newsletter out to shareholders to give them a sense that things are happening behind the scenes. At the moment, since DD left there has been complete silence and the SP has drifted down. In the absence of financials these type of more speculative stocks rely on positive market sentiment and PEB had that for some time largely due to DD. The new CEO needs to be responsive to shareholders concerns as expressed by the on-going sell off. Shareholders will not respond well to future capital raises -if there are any - unless they see the CEO/Board becoming more active.
Investor updates are out twice a year, next one due April. Seeing there was a capital raise and thereafter a slow and consistent SP decline, I agree we need more frequent comms. They have a veritable swarm or sales folks in the USA, I trust they are making headway with customers and insurers over there as well as in Asia and Oz in response to all the money shareholders have given them
Well we are due on update re Singapore. John Hopkins in the US I am very interested in seeing they have been reviewing for last 3.5 years from memory. How long did it take KP? 6 Years? I suspect Covid has slowed Sales teams getting in seeing the Sales people they need to.
Options scheme for new CEO - exercise price on the low side methinks!
https://www.nzx.com/announcements/387519
Does not give me much confidence when the option price of $1.15 and $1.25 in 5 years is so low. What am I missing here when the share price was $1.50 recently?
Options are not the likes for you and me .... they there to enrich the CEO if he hangs around and doesn't stuff up .... like hardly anything or heaps over the years ...but as they are said to 'align with shareholder interests' if the shareprice goes to 3 bucks what's a few million between friends when everybody is happy and rich ....just a small bonus for the CEO
She's tanking, call in the PPT
Still a company valued at $770m, turning over about $14m a year, and losing about $18m.
After being listed over 19 years.....
Good grief - sobering stuff...
As a holder I am perplexed why PEB have gone silent. Nothing at all from the new CEO - is he still on holiday or what? Those - like me - who participated in the capital raise are sitting on big losses. Fortunately I was into PEB way before that and sitting on gains overall, but I must admit my finger is hovering over the SELL button. if there isn't some positive operational news soon, I might have to assume that things are not going well and cut loose.
Not for me to tell you what to do but you must be getting a bit distraught to think about selling
Doesn't seem that long ago the share price was over $1.50 and punters fell over each other to get a slice of the cheap shares at $1.35
That's the capital markets for you
But one day you might see those 'hundreds of thousands of tests' or was it only 'tens of thousands' - can't recall what Swann said
[QUOTE=winner69;943560]Not for me to tell you what to do but you must be getting a bit distraught to think about selling
Doesn't seem that long ago the share price was over $1.50 and punters fell over each other to get a slice of the cheap shares at $1.35
That's the capital markets for you
But one day you might see those 'hundreds of thousands of tests' or was it only 'tens of thousands' - can't recall what Swann said[/QUOTE
Fortunately I still have profits that I can take - even if they are much less than they were a few months ago. :cool:
I am not ready to sell just yet, but I don't think I'd be the only one concerned at the slide in SP. It is normal for stocks such as PEB to slide in the absence of positive news, but I am surprised that there seems to be no support at any level. Of course, if all those new salespeople are actually doing what they were employed to do, then there may some good news coming and all will be forgiven. It was always going to be wild ride.
In the context of the present market, it doesn't seem so bad. Plenty of "quality" stocks out there that have shed ~20% or so recently. It's only natural for the more speculative ones to take a greater hit in these times. Diversification is where it's at.
M2C. In years gone past this company would continue to defend its share price. Never a good sign. Those days are behind us. Its a bear market ATM. Ride the wave. The market cap should reflect what the company is worth. Not always the case, but still a good guideline. Currently sitting at 785 million NZD circa 500 million USD. Any international diagnostic company would easily pay 2 Billion USD for this company. Will be interesting to see what happens over the next 6 months.
Show those international diagnstic companies some evidence of significant uptake and they just might! Pacific Edge have not, and I will counter - will not, produce $ proof any time soon. Whole lot of hope priced in and the market will come to terms with this in time.
Ha. When PEB becomes a revenue valuation model it will be worth well more then 2 billion USD. Agree that we would like to see more tests going through. But there is traction. To build the approvals and networks to date, you'd be looking at a 5 year project at a cost of more like 3 billion USD. A part of me feels this group should de-list now. There is no value in shareholder fatigue playing out, and under valuing a company like this. M&A Acquisitions in Diagnostics have never been higher on the tailwinds of Covid Testing. The big players have never had so much cash and are paying exorbitant premiums for companies like PEB. No mention of testing numbers or revenues in any of these deals. Perkin Elmer, Baxter, Fisher they are all paying premiums for these start ups pre significant revenue. But most of them are all VC backed, they know what they are in for. Traditional NZ NZX investors (institutions included) only want to back revenue investment models.
Hmm. Why wern't the big diagnostic firms buying this at 17 cents or at any time in the past couple of decades or so? I'd imagine they'd recognise potential in the science if they saw it.
It seems the tests are useful, but not (yet) sufficiently proven to be disruptive. Maybe big Pharma think they never will be?
I am not suggesting they can't or won't get there, but there is no proof yet of meaningful adoption or traction.
So by adoption, does the Kaiser, BC and BS, DHBs in NZ and other insurers in the US not count? Or are you expecting to see tests increase by 1,000 times to justify adoption and traction. The share price at 17cents NZD was a different company with no approved refund contracts in place. But it was obvious that they were on the cards. So yes, the big diagnostic companies missed a significant opportunity when the market cap was under 75 million NZD. But the world was different then. The covid outcome was unknown, markets were unstable, and there wasnt the free flowing cash that there is now in biotech. There is no secrete sauce to PEB, its an operational flow of testing, that is the IP. To build that would cost billions. The disruption opportunity is tricky. Urologist have always been very hesitant due to the low cost of the PEB test. They quite like the 10K traditional test, especially when they indirectly clip the ticket at about 20%. But this tactic is slowly being phased out. And to answer your question about "Why big pharma wasnt buying it over the past 2 decades. Simple, because they knew the risk and just how much cash would be required to get it where it is now. Sadly to many investors, like yourself, are coming to the end of to many flash backs to announcements that they thought would rocket the share price. But hey thanks for the cash contribution to get it where it is now!!!!! Couldnt have done it without you:)
I don't know what BC and BS are but have seen no numbers yet to demonstrate that Kaiser are using the tests in any meaningful way.
Not all the DHB's are using the tests but it is in the clinical pathway for some. This adoption in NZ over several years has not transferred to meaningful growth in NZ revenue. It is a small base agreed but with tests here costing 1/4 (?) of the US CMS price I'd have thought NZ sales might have been encouraging and suggest how the US markets might track?
Insurers in the US do not cover Cxbladder. United has a medicare policy that mirrors that of medicare but United does not cover the tests under its own policies
Medicare cover the tests where "medically necessary" . I've posted here why I think they don't fall under that category often and have yet to see any evidence that CMS "approval" has transferred to useage.
You say that the tests are cheap but in the US they can be more expensive than an in office cystoscopy. The tests are a good adjunct to the current gold standard but are not recommended by the AUA nor are they covered in the guidelines.
There is plenty of competeition in the field of bladder cancer diagnosis and the race is on. I would not be too sure about the moat you seem to think their IP offers.
edit. if you mean Bluecross blueshield, (BC BS) they do not cover Cxbladder
Curious. What non evasive diagnostic are you referring to which presents a commercial equivalent as the CX Bladder?
There are a number of factors and imponderables at play here which are affecting risk on asset perceptions being translated back into the current SP:
1. The most important factor is Lab throughput. Pacific edge reckon they have the capacity for 126000 tests. This may have increased over the last few months
2. We do not know how many tests are being performed but I think it would be fair to say nowhere near that number at the moment.
3. Is it in PEB's DNA not to report significant uptakes in tests prior to reporting time if this was happening or do they "surprise" the market with higher than expected positive news at reporting time?
4. If Cxb has a >95% NPV and supposedly a better stat than a cysto on determining the existence of BC why is it not more widely accepted by all urologists and the AUA?
5. Do the AUA have a vested interest in discounting the effectiveness of this procedure relative to cystos.
6. How influential are the AUA with insurance companies? "medically necessary" can easily be ruled out if the AUA prefer to recommend cystos vs Cxb to their association. I submit that even KP urologists do not really want to go against their associations authority.
7. Is there actually any meaningful competition that have built a significant amount of acceptable comparative data over a long period that is superior to Cxb?
So if we accept that Cxb, in terms of bladder cancer diagnosis, IS superior to all other forms of both existing and potential competition then surely its just a matter of time before it becomes the standard. IMO it appears to me that the AUA are stone walling its adoption. They have reluctantly agreed that it has some utility, which is a change from a few years ago where it was ignored.
There isn't any other non invasive diagnostic method equivalent to Cx bladder yet.
DHB in AKL has started using Cx bladder test to triage microhaematuria referral but only on small number of cases.
What more is there to know then: No credible competitive non invasive test with as higher NPV performing better than the current standard. This can't be true because if it was you would expect a surge in adoption. After 7 years of detailed data and analysis proving its efficacy something is going wrong somewhere. This is more of a market movement based on growth vs value assets, its a slow loss of faith that it will ever be adopted fully rather than being used if "medically necessary". Psychic can tell us whats not happening, who can tell us why? I'm just putting it out there.
The obvious answer for PEBS glacial adoption is that that is the pace by which the medical establishment - particularly in the US - moves at when it comes to any sort of departure from "normal" medical practice. The startup costs and regulatory hurdles are dauntingly massive. You have to have a "slam-dunk" product to get any traction at all, and even then you are fighting on a number of fronts - medical councils, clinical experts, insurance providers etc. The medical profession can be a bit of a closed shop at times, but at the end of the day I still think that PEBS products represents a step change in procedure, one that I think - if I was a patient - would be highly preferable, at least in the initial stages, to a pretty awful, invasive procedure.
I read that a lot of the capital raise funds was going towards hiring more sales people - which is the right approach (no point in having a shiny new lab if people haven't heard of the product.) Hopefully we're going to hear soon about how sales are going - they have to be tracking upwards fairly steeply. If they have stalled or gone backwards then that, I fear, could be the end of the road for PEB.
PEB trumpeted in Nov that they had 30 sales people now dedicated to the US market. An ROI on these highly paid people is essential in their next report. If all they have done is bought coffees and lunches and not signed any business and brought in additional revenue, all investors will be rightly up in arms
Currently it is on the AUA sometimes tolerated list. If it makes it to the recommended list litigation lawyers could have a field day with non users. Will that ever happen? Lots of the share price says yes, but I'm now cynical enough of the medical system in the USA to be drifting towards no. The fact the Australia and Singapore have a very slow ramp is further cause for concern.
If its that good and also non invasive it will eventually be adopted. It has to because more and more clients when they are presented with blood in the urine and see a urologist will have read up about diagnostic methods in determining what could be causing it and how to test for it. I would go for Cxb any day of the week rather than risk a cysto with the risk of side issues. Its not uncommon for medical facilities to be slow with adoption. PEB need to work with the AUA and work out what the issue is. It can't be lack of clinical evidence after 7 years of data collection....surely?
PEB is one of those companies that just need a hint of a new institutional revenue source and you could see a move of 40%+ in the SP with no sellers in-between
keep in mind also that they are working on non invasive tests for other common diseases.
Are the tests that good? Are they good enough to replace cystoscopy? If they were as you say, and there was sufficient evidence available to support adoption, then I say you would have proof in uptake by now. Simple.
The AUA don't recommend Cxbladder at all, you will find no specific mention of it in the guidelines. All they have done is to say (with the very weakest of recommendations) is that urinary biomarkers might be used in certain situations as an adjunct. But generally, the use is not recommended.
It is very difficult for us to understand the why's in such a (well to me anyway) complex game. If we are to believe what PE tell us, then yes, the tests would seem to be an easy choice over cystoscopy. But the stats bandied about, the NPV etc perhaps do not provide the complete picture. Someone might like to clarify for me but I think the results will depend on the the group being tested, the grade of cancer, and role of the test etc. What are the false positives? How reliable and independent were the studies (most of the studies are by staff or associates of Pacific Edge)
So I now simply look for evidence that what Pacific Edge say is happening, is happening. And I have yet to see it, on oh so many fronts over the years. I've seem some encouraging independent studies on quite a few of the Cxbladde tests, but most seem to finish off with the "more evidence required' sort of thing.
I will attempt to embed a comparative table from a recent study and provide the link. Is Cxbladder monitor the best choice?
This suggests that from 1000 patients Cxbladder Monitor would have avoided 500 cystoscopies while the newer tests Uromonitor and Epicheck would have avoided 706 and 740 respectively. Cxbladder was lowest of the four, yet highest in unnecesssry cysto's (false positives)
How certain should we be?
Attachment 13576
https://www.sciencedirect.com/scienc...88931121001838
That's pretty fair comment Psychic thanks.
I think that we are all a little bewildered by what is being put out there and whether the tests have been conducted over the same group of 1000 people at the same stage. Uromonitor and Epicheck show some pretty impressive results but over what time frame and samples of different stages have they been conducted?
Also, is there any evidence that the AUA are recommending any UBT's? It looks like its just the same old story waiting for a hundred years of evidence!
We know that survey was published by European oncology, but again some of the UBT's have not been around long enough for any performance reliability, and that is pretty clearly stated.
I would have thought that KP would have done a lot of research before adopting Cxb. Thats a positive for Cxb.
DNA UBT types appear to be new to market and less proven than MRNa types.(Cxb)
Harry, sorry no -the comparison has been made by pooling the results of published studies, so it is not as if a group of 1000 BC patients have each been tested by the four markers. But I imagine it would have only been published if the method and reasoning were valid. I see Yair Loten was involved in some capacity, a name that is on the Author list of many studies into bladder cancer diagnosis, I think he was also on the advisery panel for PEB at one time?
And yes, the other tests are in various stages of commercialisation. Who knows if they will make it either. I guess my point was that Cxb Monitor was supposed to be the mover and shaker with the high NPV etc but you can see that it can be bettered and arguably, it might be the unacceptable level of false positives stopping it from gaining acceptance, as I think appies to the other CXb tests..
Yes KP have completed a lot of research over the years into ways they might reduce cystoscopies, well before PE approached them with Triage. But go back and look at the announcements. Years that "trial" went on, and nothing was announced. Essentially they didn't go with Triage. Later, PE say they went with monitor (?) and later still, all cxb tests. But I am very very doubtful they are using many as I am doubtful CMS are.
Lack of public updates from new CEO after investing proceeds from Cap Raise for new US based sales team. CEO and management invested well aware of decline in SP. Haven't made announcement to support or prevent such, likelihood waiting for March announcement to have some impact rather than feather things in the interim. Giving the sales team time to become established. Timing not ideal with Pandemic/Ukraine. Most likely saving any positive news may balance out the overall global poor market conditions. Update most likely won't show much advancement in immediate revenue/sales, but shareholders can hope indication of progress with networking and relationships forming for integration.
The fact still remains, if you asked anyone who has had a cystoscopy if they would rather have used cx-bladder if it were available to them, pretty sure we know what the answer would be. Main reason SP has been declining is obviously a combination of overall market influences of recent months, pandemic, interest rates and Putin's insanity. At the point now where it could be viewed the perfect storm and SP at a bargain to last cap raise 1.35 and recent SP 1.5 plus. Coming out of pandemic, world re-opening up, boarders opening. Tables very soon turning against Russia, Putin losing following of the Russian people themselves including his own troops. The 'Fear factor' involved will subside, likely now to see a pretty solid rebound in market and especially Tech stocks (PEB following this trend). Not unlikely could see these bounces as swiftly as the increases in PEB SP seen last year when jumped 20 - 40% within ~24-48hrs each time.
A man see's what he wants to see I guess...
If I were asked how I'd like my cancer diagnosed, I'd probabaly go with the recommendation of my Urologist. But I do recognise that personal choice over science and informed opinion has become something of a thing these days.
If there was ever a time when a simple, reliable, established home test might defer an office cystoscopy, the last few years have been extraordinary.
If a share price makes huge gains on the back of misleading and/or generally misunderstood announcements, my worry would be that it can fall as hard, if not harder, when the market sees no follow through. Been there, done that. Bloody hurts.
I'm not sure that's a fair representation. It's not a case of personal opinion over science - it's all science. PEB have largely cleared the regulatory hurdles, they've done the trials and the results are encouraging. Whether you think the results or even the product itself is worthy of it's share price or market attention, then that is another matter, and one for the individual investor to judge for themselves. No one has a crystal ball that can give's them the right to say their opinion is the definitive one and everyone else's is uninformed.
As I've said, this year will be a make or break year for PEB for many investors. They've got the beginnings of market traction and they've got the funds and sales force. if that starts to translate into throughput then the SP will bounce rapidly as it has done before. If not, the market will deliver i's judgement.
Maxtrade suggested folk would choose Cxbladder over a cystoscopy. Unless one has the necessary background to make an informed decision about the reliability of a diagnostic test then I think most, with their lives at stake, would follow the recommendation of someone who is able to make an informed decision. The AUA make informed decisions, and they do not recommend it. The tests are not insured.
I didn't for a moment intend that everyone should think what I do or suggest opinions other than mine wer misinformed. This is a forum, we discuss stocks.
Fair enough. I agree this is a discussion, that encompasses all types of investors with different approaches to investing and different appetites for risk.I didn't see where you were going with "personal choice over science" as if that was a binary thing. Nor with SP movements on the back of misleading announcements. Is that a PEB thing or a general comment?
CXbladder is not designed to replace cystoscopy, rather to augment it. It's not an either or. Where there is, for a example a small amount of urine in the blood (hematuria), the options in the past have been to either ignore it, or go through an invasive procedure that may turn out, in many or most cases, to be completely unnecessary. CXbladder is accurate enough to be able to give an indication of a potential problem ( in which case a cystoscopy may be requested) or to give an all-clear (perhaps with a follow up scan). It's a useful middle path, diagnostic tool. The AUA's own journal of urology said as much in it's performance trial of CXbladder last year:
"For various reasons, many patients who present to primary care with hematuria are not referred for workup. However, the availability of a highly reli- able urine test that enriches the diagnostic yield in the hematuria population improves the proportion of at-risk patients being evaluated, resulting in a higher rate of early UC detection in the patients who are referred for workup. Cxb’s high level of clinical resolution to rule out patients without UC and prioritize others is likely to reduce referral time and enable specialist resources to be focused on patients most likely to have UC, providing a
clinically meaningful benefit and reducing the cost of care."
There re many health providers here in NZ, AUS and the US (including Medicare) that are now using CXBladder. They wouldn't do so if they didn't think it was diagnostically safe. The evidence is already out there, that it is a safe, useful diagnostic tool. The challenge is to get greater uptake. If PEB could get say, Johns Hopkins, on board, wide scale acceptance would follow. And we could all retire as millionaires.
Cxbladder can be used in conjunction with Cytoscopy. It can help indicate when a Cytoscopy can be recommended to confirm a diagnosis. The advantage is in many cases it can be used to indicate when a Cytoscopy may NOT be needed. ie a Precursor to assist. Non-invasive diagnostic laboratory tests like Cxbladder may be able to accurately rule out bladder cancer without the expense or discomfort of an invasive procedure such as cystoscopy. Multiple trials have demonstrated Cxbladder’s superior performance versus other urine-based tests in accurately ruling out and detecting bladder cancer. There are numerous peer reviewed scientific published studies on Cxbladder urine tests correlated with confirmation of cytoscopy results. The results are very positive. This cancer test has be shown it can reduce the number of invasive procedures required. This is where Cxbladder excels and can establish its place. That is what I meant about stating for those who could opt for a less invasive bladder test versus going straight into a Cytoscopy. Hope that helps clarify.
Yes, agree with that, thanks.
Lounge lizard, yes the misleading announcements comment I made relates to PEB.
Been some time since I've looked at PEB, but I see the price has near halved in the last 6 months. I take it those 'tens of thousands' of tests still haven't eventuated?
Looks like the local instos have taken advantage of the current discount to accumulate.
Announcement at market close today, Harbour Asset and Jarden have added 20 million shares between them from my interpretation.